All In Biotech

Investigational drug · Phase 2

MT-4561

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer.

Phase 2

Last checked: Nov 19, 2026Latest source record: Dec 11, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "MT-4561"

First trial start

2025

Apr 18, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "MT-4561", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Head and Neck Squamous Cell Carcinoma (HNSCC)
  • Non-small Cell Lung Cancer (NSCLC)
  • Esophageal Cancer
  • Gastric Cancer
  • Biliary Tract Cancer
  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • Breast Cancer
  • Ovarian Cancer
  • Cervical Cancer
  • Endometrial Cancer

Approved drugs for the same conditions: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Ovarian cancer · Pancreatic cancer · Stomach and esophageal cancer · Oncology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "MT-4561" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 1 on PubMed

Also in development for Head and Neck Squamous Cell Carcinoma (HNSCC)

  • INBRX-106OrdastobartPhase 31 trial

    Inhibrx Biosciences, Inc · Head and Neck Squamous Cell Carcinoma (HNSCC), HPV Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC)

  • AK129Phase 22 trials

    Akeso · Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal Adenocarcinoma

  • AP203Phase 21 trial

    AP Biosciences Inc. · Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC)

  • FDC fianlimabPhase 21 trial

    Regeneron · Head and Neck Squamous Cell Carcinoma (HNSCC)

  • GEN1042Phase 21 trial

    Genmab · Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)

  • GTAEXS617REC-617Phase 21 trial

    Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. · Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.